<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665141</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-ALER-2021-01</org_study_id>
    <nct_id>NCT04665141</nct_id>
  </id_info>
  <brief_title>Similarities and Differences of Biological Therapies for Severe Asthma.</brief_title>
  <official_title>Similarities and Differences of Biological Therapies for Severe Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Regional de Malaga</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an ambispective multicenter longitudinal observational study to evaluate the efficacy&#xD;
      and safety profile of biological therapies in patients diagnosed with severe asthma in real&#xD;
      life conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of biologicals to treat severe asthma has been implemented in a regular basis while&#xD;
      information on long term effectiveness and safety is lacking. It is necessary to establish&#xD;
      strategies to closely monitor the possible occurrence of reactions, adverse effects of&#xD;
      innovative biological medicines used to treat severe asthma.&#xD;
&#xD;
      In this study the investigators want to evaluate the comparative effectiveness, utilization&#xD;
      patterns, long-term safety, and use in special groups in real-life conditions in severe&#xD;
      asthma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment dose scheduling and changes of dose throughout the study.</measure>
    <time_frame>2 years after inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatment discontinuations and causes of interruption throughout the study.</measure>
    <time_frame>2 years after inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Relevant Treatment-Related Adverse Events recorded throughout the study.</measure>
    <time_frame>2 years after inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Treatment-Related Adverse Events recorded throughout the study.</measure>
    <time_frame>2 years after inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of asthma control during the treatment.</measure>
    <time_frame>2 years after inclusion</time_frame>
    <description>Number of asthma exacerbations, change in FEV1, ACT, and blood eosinophilia, need of add-on medication, inhaled medication and systemic corticosteroids.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <description>Patients with severe asthma being treated with non-biological standard therapies, mainly systemic corticosteroids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biological therapies</arm_group_label>
    <description>Patients with severe asthma being treated with omalizumab, mepolizumab, reslizumab, benralizumab, or dupilumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mepolizumab</intervention_name>
    <description>Mepolizumab will be prescribed freely by the treating physician according to real-life conditions.</description>
    <arm_group_label>Biological therapies</arm_group_label>
    <other_name>Nucala®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>Omalizumab will be prescribed freely by the treating physician according to real-life conditions.</description>
    <arm_group_label>Biological therapies</arm_group_label>
    <other_name>Xolair®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Reslizumab</intervention_name>
    <description>Reslizumab will be prescribed freely by the treating physician according to real-life conditions.</description>
    <arm_group_label>Biological therapies</arm_group_label>
    <other_name>Cinqair®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Benralizumab</intervention_name>
    <description>Benralizumab will be prescribed freely by the treating physician according to real-life conditions.</description>
    <arm_group_label>Biological therapies</arm_group_label>
    <other_name>Fasenra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <description>Dupilumab will be prescribed freely by the treating physician according to real-life conditions.</description>
    <arm_group_label>Biological therapies</arm_group_label>
    <other_name>Dupixent®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients, adults and children, with a diagnosis of severe asthma in the participating&#xD;
        centers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals of any age: adults and children.&#xD;
&#xD;
          -  Diagnosis of severe asthma as given by the treating physician, and defined as an&#xD;
             asthma that remains uncontrolled in despite adherence with maximal optimized therapy&#xD;
             and treatment of contributed factors, or asthma that worsens when high dose treatment&#xD;
             is decreased.&#xD;
&#xD;
          -  Being treated or not (control group) with biological drugs.&#xD;
&#xD;
          -  Signed Informed Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marta López de Calle</last_name>
    <phone>+34948425600</phone>
    <email>mlopezdecal@unav.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Civil-Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª José Torres</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
    <mesh_term>Benralizumab</mesh_term>
    <mesh_term>Reslizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

